Latest News | Projects Achievements

  • Eva Molero gives talk on collaborative research projects at the Ramon Llull University

    Eva Molero gives talk on collaborative research projects at the Ramon Llull University

    This Tuesday University Ramon Llull has organised one of their "Professors` day" sessions at the Institute of Chemistry IQS. The session titled “Innovation in Research and Academia” gathered several experts in biomedical research to share their knowledge with the professors of IQS. Eva Molero, SYNAPSE CEO, has been invited to talk about the impact in collaborative research projects. Eva talked about international consortium structure and its complexity. She explained why the participation of different stakeholders is often needed to optimally address research challenges and why public-private partnerships are becoming more common. The talk was followed by a short debate among …
  • EPAD and AMYPAD presented at the AAIC in Chicago, US

    EPAD and AMYPAD presented at the AAIC in Chicago, US

    The Alzheimer’s Association International Conference (AAIC) is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic science and clinical researchers, next generation investigators, clinicians, and the care research community to share research discoveries that will lead to better treatment and diagnosis of Alzheimer’s disease. Over 5000 thousand attendees from 68 countries gathered this year at the AAIC in Chicago during the 14th – 18th of July, to share their knowledge in the field of dementia research. For the first time EPAD study was exhibited. The EPAD booth was a great meeting area for …
  • Meet our projects at the IMI Scientific Symposium in Brussels

    Meet our projects at the IMI Scientific Symposium in Brussels

    This year Innovative Medicines Initiative (IMI) is celebrating its10th anniversary, and this comes precisely in a year when Synapse is also celebrating its first decade of existence. From 2008 Synapse and IMI have grown side by side. The IMI has launched over 100 projects over the last ten years, and 13 of them are managed by our project managers. During the 22nd and 23rd of October, in Brussels, IMI is organising Scientific Symposium, meant to bring together IMI projects` stakeholders, partners and researchers to share projects` achievements and learn from one another. The Scientific Symposium will feature more than 80 posters, …
  • Synapse participates in the 3rd Real World Epidemiology Oxford Summer School

    Synapse participates in the 3rd Real World Epidemiology Oxford Summer School

    Synapse has sponsored the third edition of the Real World Epidemiology Oxford Summer School. This course is aimed to explore the existing sources of real world data, discuss common types of study and designs for its use, and look in-depth into the issues and solutions linked to big health data usage. The topic is very much aligned with many of the projects and initiatives that Synapse is currently managing (ROADMAP, EU-ADR Alliance, etc.). The course is now a well-established event and has been fully booked this year. The audience ranges from pharmacists, clinicians, academics (including statisticians, epidemiologists, and related MSc/PhD …
  • SYNAPSE – Facts and Figures

    SYNAPSE – Facts and Figures

    Ten years ago Innovative Medicines Initiative Joint Undertaking (IMI-JU) was created as a unique public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA) aiming to accelerate development of innovative medicines. On April 2008 IMI-JU launched its first call for proposals. Carlos Díaz and Eva Molero were at that time working at the Barcelona Municipal Institute for Medical Research managing European projects. That same year SYNAPSE was created, initially to manage a public private partner in AIDS vaccine – HIVACAT. The first IMI project in which SYNAPSE was a partner was the eTOX project, steming from …
  • ADVANCE BLUEPRINT IS OPEN FOR PUBLIC CONSULTATION

    ADVANCE BLUEPRINT IS OPEN FOR PUBLIC CONSULTATION

    Vaccines undergo rigorous testing prior to licensing for use, however it is important that the safety of vaccines is monitored on an ongoing basis. The ADVANCE project, managed by Synapse and sponsored by the Innovative Medicines Initiative Joint Undertaking (IMI JU) and the EFPIA companies, is aimed to review, develop and test methods, data sources and procedures for an efficient and sustainable pan-European framework that can rapidly deliver robust, quantitative data for the assessment of the benefits and risks of marketed vaccines. This framework will make it easier for regulators and public health authorities to make fast, more informed decisions …
  • SYNAPSE: from project management to value creation

    SYNAPSE: from project management to value creation

    SYNAPSE is celebrating its 10th anniversary this year. The company has been steadily growing in size, expertise and in the complexity of the projects it is involved in. The SYNAPSE Executive Committee is fully engaged in a reflection to take stock of what has been achieved so far and to identify and prioritse new areas for development. Last 15th of June a number of long term partners and collaborators were invited to contribute to this reflection during a day-long session in Barcelona. The group joined the SYNAPSE Executive Committee and revisited the company’s trajectory, analysed strenghts and weakness and discussed …
  • RESCEU 2nd General Assembly meets 18 months after the start of the project to discuss the progress made and present first results

    RESCEU 2nd General Assembly meets 18 months after the start of the project to discuss the progress made and present first results

    The Second General Assembly Meeting of the REspiratory Syncytial virus Consortium in EUrope (RESCEU) took place on 21-22 June at St Anne’s College in Oxford, bringing together about 100 participants from the 18 project’s partners and representatives from all the work packages. Affiliated Partners representatives, RESCEU Advisory Boards members and other relevant stakeholders, such as the World Health Organization, were also invited to attend and provide their perspective on the project. RESCEU aims to develop robust evidence on RSV disease burden and economic impact and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics. In its effort …
  • SYNAPSE is celebrating its 10th anniversary

    SYNAPSE is celebrating its 10th anniversary

    This year SYNAPSE is proud to celebrate its 10th anniversary with a highly positive balance: 25 projects in total, almost 20 people in our team and a large network of partners from a great variety of stakeholders at both national and international levels (pharmaceutical companies, biotechnology companies, research centres, academia, hospitals, regulatory authorities, public health authorities, etc.). SYNAPSE creates value in innovative and collaborative partnerships in the biomedical sector.  By managing a portfolio of large and ambitious projects in the health domain, SYNAPSE enables synergies across the projects partnership towards successful achievement of results. SYNAPSE has become a partner of …
  • The ADVANCE Steering Committee met at Món St. Benet to define the last year project workplan and sustainability

    The ADVANCE Steering Committee met at Món St. Benet to define the last year project workplan and sustainability

    The ADVANCE project represents unique collaboration between key stakeholders in the sector, including European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), national public health and regulatory bodies, vaccine manufacturers, SMEs, and academic institutions. ADVANCE aims to review, develop and test methods, data sources and procedures which should feed into a blueprint of an efficient and sustainable pan-European framework that can rapidly deliver robust quantitative data for the assessment of the benefits and risks of vaccines that are on the market. The framework supports health professionals, regulatory agencies, public health institutions and the general public make better …
  • The 3rd eTRANSAFE Consortium Meeting held in Barcelona on the 4th and 5th of June

    The 3rd eTRANSAFE Consortium Meeting held in Barcelona on the 4th and 5th of June

    Members of the 27 eTRANSAFE Consortium partners gathered for two days in Barcelona to review the progress of the project done in the past months. eTRANSAFE aims to develop predictive services, contributing to the safety assessment of chemical compounds. Integrative analysis of preclinical and clinical data for generation of candidate translational biomarkers is another important goal of the project. Francois Pognan (Novartis) and Carlos Díaz (Synapse) gave an overall vision and management of the project, followed by Eva Molero`s (Synapse) talk on the need to consider sustainability implications of any decision made in the project from the very start. The …
  • EPAD presented its next steps at the General Assembly Meeting held in Amsterdam

    EPAD presented its next steps at the General Assembly Meeting held in Amsterdam

    The fourth EPAD General Assembly was held on May 23rd-35th in Amsterdam under the banner “How to Assure Sustainability?”. Almost 180 representatives from 37 partner institutions and several other associated institutions gathered to discuss past achievements, challenges faced so far and the expected future outcomes. The EPAD project aims to develop an infrastructure that efficiently enables the undertaking of adaptive, multi-arm Proof of Concept studies for early and accurate decisions on the ongoing development of drug candidates for Alzheimer Disease. To ensure the success of the project, efforts within all work packages are continuously made as to accelerate the Trial …
  • Join the DRIVE network!

    Join the DRIVE network!

    The DRIVE Project aims at developing a governance model between public and private entities to enable a sustainable network of influenza vaccine effectiveness (IVE). Influenza is a major public health issue, it is thought to infect over 50 million of EU citizens. Vaccines are the cornerstone of preventing influenza, but their effectiveness can vary from year to year and across recipient groups. DRIVE will set up a platform, bringing together all stakeholders, to explore brand-specific effectiveness estimates for all influenza vaccines used in the EU each season, that will ultimately have a positive impact on European citizens public health. Starting …
  • AMYPAD diagnostic and patient management study (DMPS) enrolled its first research participant in Geneva last Friday

    AMYPAD diagnostic and patient management study (DMPS) enrolled its first research participant in Geneva last Friday

    The Amyloid imaging to prevent Alzheimer’s Disease project (AMYPAD) aims at studying the onset, dynamics, and clinical relevance of brain β-amyloid in the spectrum from normal aging towards mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). AMYPAD studies the value of using PET (positron emission tomography) imaging for β-amyloid deposits, with the goal to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. Within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project, researchers aim to determine the usefulness of early …
  • The first TransQST General Assembly meeting held in Finland

    The first TransQST General Assembly meeting held in Finland

    The TransQST project, launched in January 2017, aims to develop novel computational approaches using the best available data from the public and private domains to improve the assessment of drug candidates before undergoing clinical testing phase. TransQST work focuses on vital organs - liver, kidney, cardiovascular and gastrointestinal systems. The first TransQST General Assembly meeting took place on the 25th and 26th of April 2018 in Vihti, Finland. The focus of the two-day meeting was on the last updates from work packages as well on establishing the roadmap for the Early Review of the project that will take place on …
  • Synapse gathers the ROADMAP consortium partners for the 5th General Assembly Meeting

    Synapse gathers the ROADMAP consortium partners for the 5th General Assembly Meeting

    ROADMAP aspires to create the conditions for an open collaboration that yields consensual and efficient uses of RWE for the benefit of Alzheimer’s Disease patients and their caregivers. ROADMAP aims to deliver a series of data integration methods and tools for patient outcomes, which will provide the foundation for the future European RWE platform on AD. This year the ROADMAP general assembly was held in Barcelona during April 25th-26th. The consortium partners met to review ROADMAP achievements, and to discuss next steps. Key deliverables expected from the project are:  1) Develop recommendations on RWE appropriate AD‐related cognitive, functional, and behavioural …
  • Synapse organises the 6th iPiE Forum Meeting at the Biomedical Research Park of Barcelona

    Synapse organises the 6th iPiE Forum Meeting at the Biomedical Research Park of Barcelona

    iPiE (Intelligence-led Assessment of Pharmaceuticals in the Environment) aims to develop predictive tools that use information from toxicological studies, in silico models and existing datasets on environmental fate and effects of APIs (Active pharmaceutical ingredients), to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for environmental risk assessment. The consortium comprises leading experts in data management and computational modelling, pharmacology, environmental chemistry, predictive (eco)toxicology and risk assessment. The 6th iPiE Forum meeting, held on April 24th-25th in Barcelona, was focused on progress to the development of guidance on how the established approaches and expert …
  • EMIF organises a public symposium “Liberating Evidence from European Health Data” within its closing meeting in Brussels

    EMIF organises a public symposium “Liberating Evidence from European Health Data” within its closing meeting in Brussels

    During the 16th – 18th of April, the closing EMIF meeting was held in Brussels. The main issues addressed during the meeting were project’s objectives and outcomes, impact, sustainability and lessons learned. The mission of the EMIF framework is to improve identification, access and assessment, and reuse of health data. The EMIF project, funded by IMI and started in January 2013, was aiming at developing a framework for evaluating, enhancing and providing access to human health data across Europe. The development of common technical and governance solutions, to improve access and use of health data, resulted in a secure online …
  • PARADIGM, a new IMI project managed by SYNAPSE centered in Patient Engagement, kicks off in Brussels, with the 1st Open Patient Engagement Forum

    PARADIGM, a new IMI project managed by SYNAPSE centered in Patient Engagement, kicks off in Brussels, with the 1st Open Patient Engagement Forum

    The PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines) project, funded by IMI-JU 2, was officially launched in Brussel on April 10th. The PARADIGM consortium is led by the European Patients’ Forum and EFPIA and gathers 34 partners comprising patient organisations, regulatory bodies, universities, non-for-profit organisations, SMEs, trade associations and pharmaceutical companies. PARADIGM’s mission is to provide a unique framework that enables sustainable patient engagement and demonstrates the ‘return on the engagement’ for all players. PARADIGM will build on existing tools to integrate the needs, perspectives and expectations of all actors involved and will provide a sustainable …
  • SYNAPSE attended the first Observational Health Data Sciences and Informatics (OHDSI) Symposium in Rotterdam

    SYNAPSE attended the first Observational Health Data Sciences and Informatics (OHDSI) Symposium in Rotterdam

    The first European OHDSI Symposium called "Bridging Europe” was held in Rotterdam on the 23rd and 24th of March. The Observational Health Data Sciences and Informatics (OHDSI) program is a multi-stakeholder, interdisciplinary collaborative initiative to leverage the value of health data through large-scale analytics, and it has established a global network of researchers and observational open-source health databases. OHDSI Europe is led by the Erasmus University Medical Center in Rotterdam. Peter Rijnbeek (Erasmus MC), welcomed over 200 international participants that were engaged in different sessions and tutorials. During the Symposium, several posters were presented, some of them stemming from the EMIF …

Recent Tweets

Follow Us

CONTACT DETAILS

Tel: +34 93 300 6061 | info@synapse-managers.com
Diputación 237, Ático 3ª. 08007 Barcelona (Spain)
Velázquez, 94. 1º Planta, 28006 Madrid (Spain)

Click to open a larger map

 
 

HIGHLIGHTS

EU-ADR Alliance
A federated collaborative framework for drug safety studies

Synapse Flyer
A quick overview of our Background and Services (PDF format)